Bone-marrow-derived Myofibroblasts Contribute to the Cancer-induced Stromal Reaction
Overview
Authors
Affiliations
To confirm whether human cancer-induced stromal cells are derived from bone marrow, bone marrow (BM) cells obtained from beta-galactosidase transgenic and recombination activating gene 1 (RAG-1) deficient double-mutant mice (H-2b) were transplanted into sublethally irradiated severe combined immunodeficient (SCID) mice (H-2d). The human pancreatic cancer cell line Capan-1 was subcutaneously xenotransplanted into SCID recipients and stromal formation was analyzed on day 14 and on day 28. Immunohistochemical and immunofluorescence studies revealed that BM-derived endothelial cells (X-gal/CD31 or H-2b/CD31 double-positive cells) and myofibroblasts (X-gal/alpha-smooth muscle actin or H-2b/alpha-smooth muscle actin double-positive cells) were present within and around the cancer nests. On day 14, the frequencies of BM-derived endothelial cells and BM-derived myofibroblasts were 25.3+/-4.4% and 12.7+/-9.6%, respectively. On day 28, the frequency of BM-derived endothelial cells was 26.7+/-9.7%, which was similar to the value on day 14. However, the frequency of BM-derived myofibroblasts was significantly higher (39.8+/-17.1%) on day 28 than on day 14 (P<0.05). The topoisomerase IIalpha-positive ratio was 2.2+/-1.2% for the H-2b-positive myofibroblasts, as opposed to only 0.3+/-0.4% for the H-2b-negative myofibroblasts, significant proliferative activity was observed in the BM-derived myofibroblasts (P<0.05). Our results indicate that BM-derived myofibroblasts become a major component of cancer-induced stromal cells in the later stage of tumor development.
Tsukamoto S, Kodama T, Nishio M, Shigeoka M, Itoh T, Yokozaki H Cells. 2024; 13(20.
PMID: 39451200 PMC: 11506654. DOI: 10.3390/cells13201682.
PTGES is involved in myofibroblast differentiation via HIF-1α-dependent glycolysis pathway.
Lin M, Lee Y, Liao J, Chou C, Yang Y J Cell Mol Med. 2024; 28(20):e70157.
PMID: 39417702 PMC: 11484478. DOI: 10.1111/jcmm.70157.
Mesenchymal stromal cells as cancer promoters.
Antoon R, Overdevest N, Saleh A, Keating A Oncogene. 2024; 43(49):3545-3555.
PMID: 39414984 PMC: 11602730. DOI: 10.1038/s41388-024-03183-1.
Saude-Conde R, Arcay Ozturk A, Stosic K, Azurmendi Senar O, Navez J, Bouchart C Biomedicines. 2024; 12(3).
PMID: 38540204 PMC: 10968082. DOI: 10.3390/biomedicines12030591.
Ou S, Kim T, Jung E, Shin S BMB Rep. 2023; 57(5):238-243.
PMID: 37915133 PMC: 11139678.